» Articles » PMID: 11752464

Oxygen Radical Inhibition of Nitric Oxide-dependent Vascular Function in Sickle Cell Disease

Overview
Specialty Science
Date 2001 Dec 26
PMID 11752464
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma xanthine oxidase (XO) activity was defined as a source of enhanced vascular superoxide (O(2)( *-)) and hydrogen peroxide (H(2)O(2)) production in both sickle cell disease (SCD) patients and knockout-transgenic SCD mice. There was a significant increase in the plasma XO activity of SCD patients that was similarly reflected in the SCD mouse model. Western blot and enzymatic analysis of liver tissue from SCD mice revealed decreased XO content. Hematoxylin and eosin staining of liver tissue of knockout-transgenic SCD mice indicated extensive hepatocellular injury that was accompanied by increased plasma content of the liver enzyme alanine aminotransferase. Immunocytochemical and enzymatic analysis of XO in thoracic aorta and liver tissue of SCD mice showed increased vessel wall and decreased liver XO, with XO concentrated on and in vascular luminal cells. Steady-state rates of vascular O(2)( *-) production, as indicated by coelenterazine chemiluminescence, were significantly increased, and nitric oxide (( *)NO)-dependent vasorelaxation of aortic ring segments was severely impaired in SCD mice, implying oxidative inactivation of ( *)NO. Pretreatment of aortic vessels with the superoxide dismutase mimetic manganese 5,10,15,20-tetrakis(N-ethylpyridinium-2-yl)porphyrin markedly decreased O(2)( small middle dot-) levels and significantly restored acetylcholine-dependent relaxation, whereas catalase had no effect. These data reveal that episodes of intrahepatic hypoxia-reoxygenation associated with SCD can induce the release of XO into the circulation from the liver. This circulating XO can then bind avidly to vessel luminal cells and impair vascular function by creating an oxidative milieu and catalytically consuming (*)NO via O(2)( small middle dot-)-dependent mechanisms.

Citing Articles

The Redox Process in Red Blood Cells: Balancing Oxidants and Antioxidants.

Daraghmeh D, Karaman R Antioxidants (Basel). 2025; 14(1).

PMID: 39857370 PMC: 11762794. DOI: 10.3390/antiox14010036.


Soluble guanylate cyclase stimulators and activators: new horizons in the treatment of priapism associated with sickle cell disease.

Pereira D, Silveira T, Calmasini F, Silva F Front Pharmacol. 2024; 15:1357176.

PMID: 38384294 PMC: 10879333. DOI: 10.3389/fphar.2024.1357176.


Oxidative Stress in Healthy and Pathological Red Blood Cells.

Orrico F, Laurance S, Lopez A, Lefevre S, Thomson L, Moller M Biomolecules. 2023; 13(8).

PMID: 37627327 PMC: 10452114. DOI: 10.3390/biom13081262.


Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study.

Kotozaki Y, Satoh M, Nasu T, Tanno K, Tanaka F, Sasaki M Biomedicines. 2023; 11(3).

PMID: 36979733 PMC: 10045414. DOI: 10.3390/biomedicines11030754.


Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura.

Joffre J, Raia L, Urbina T, Bonny V, Gabarre P, Missri L Crit Care. 2023; 27(1):116.

PMID: 36944989 PMC: 10028781. DOI: 10.1186/s13054-023-04405-w.


References
1.
Royall J, Gwin P, Parks D, Freeman B . Responses of vascular endothelial oxidant metabolism to lipopolysaccharide and tumor necrosis factor-alpha. Arch Biochem Biophys. 1992; 294(2):686-94. DOI: 10.1016/0003-9861(92)90742-f. View

2.
Solovey A, Gui L, Key N, Hebbel R . Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998; 101(9):1899-904. PMC: 508776. DOI: 10.1172/JCI1932. View

3.
White C, Brock T, Chang L, Crapo J, Briscoe P, Ku D . Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994; 91(3):1044-8. PMC: 521450. DOI: 10.1073/pnas.91.3.1044. View

4.
Kooij A . A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase. Histochem J. 1994; 26(12):889-915. View

5.
Butler R, Morris A, Belch J, Hill A, Struthers A . Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000; 35(3):746-51. DOI: 10.1161/01.hyp.35.3.746. View